Monday, 26 Aug 2019

You are here

The RheumNow Week in Review – 7 April 2017

Dr. Jack Cush reviews highlights from this week's meeting at the Cleveland Clinic Foundation - Biologics Summit VII; and of course a few other tweets and journal articles:

  1. Dr Ritchlin Risk factors for PsA: obesity, nail dystrophy, smoking, severe psoriasis, nail dystrophy, trauma, Fam Hx PsA, Rubella vaccination
  2. Dr. Ritchlin-30% psoriasis pts develop PsA, mechanisms unknown. enthesitis driven by biomechanical factors, arthritis involves IL-17, IL-23
  3. Psoriatic Genetics: Dr Chris Ritchlin shows HLA- C*0602 seen in 57% of Psoriasis patients, but only 28% of Psoriatic arthritis. #CCFSummit
  4. FDA approves 23andme to market genetic tests for Alzheimers,Parkinsons, celiac, dystonia, Gaucher, hemochromatosis
  5. Dr Torgerson Complement deficiency in SLE: C2 40% homozytotes get lupus GN; C4 - 75% get GN; C1q/r/s def 90% get SLE or GN, usually young
  6. Dr Troy Togerson humans make 100 billion PMNs qd, live ~6.5 hrs, removed by complement and phagocytes. "Neutrophils live fast and die hard" 
  7. Dr Holers Mucosal evidence: IgA autoAb present, airway dz in ACPA+ FDR, IgA plasmablasts, dysbiosis (gut, periodontal) in At risk individuals
  8. Dr. Holers - Stopping smoking will reduced risk but data from Nurses Health Study says you need to be off for 20yrs…
  9. Dr M Holers shows 1st Degree relatives (FDR) about 16% are RF or CCP positive, increased by smoking @CCF Biologics Summit VII
  10. Dr McInnes -"RA synovium in inflammation tells us much, but the synovium in remission is likely to tell us more"
  11. Dr McInnes - in #RA the immune system dynamics change as the disease evolves; yet our therapies/approach unchanged and not keenly targeted
  12. Dr Iain McInnes "One of the major lessons in the last decade is that we are bad at choosing the right target" CCF Biologic Therapies Summit
  13. Statin Necrotizing myopathy review 100 pts, 65yrs, CK 6853, 100% HMG-CoA reductase Ab+, most on DMARDs
  14. FDA grants "breakthrough status" (expedited review) for Rituximab in Pemphigus Vulgaris based on recent Lancet study
  15. Abbvie announces that Humira is now FDA approved for use in severe finger nail psoriasis.
  16. FDAs Oncology Advisory Committee votes 11-0 approve subcutaneous rituximab for lymphoma & CLL. Given in minutes not hours
  17. Auranofin repurposed for use in cancer, resistant bacterial, fungal & parasitic infections
  18. Healthy Bones Formed During Adolescence 
  19.  Abatacept Use During Surgery
  20. The Great Masquerader. 
The author has received compensation as an advisor or consultant on this subject

Rheumatologists' Comments

A lot of time and money is wasted chasing ghosts associated with FMS. Another problem is when FMS coexists with bonafide disease including RA, SLE etc. More chasing ghosts. If anything improves with a prednisone challenge, the FMS must be set aside and the evaluation of symptoms must proceed in spite of the FMS.

More Like This

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings;; and more.

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.